Inclusion Criteria:

          1. Newly diagnosed, histologically proven EBV-positive Diffuse large B-cell lymphoma
             A.EBV positivity: The presence of EBER-positive tumor cells ≥ 20% B.DLBCL based on the
             WHO classification 2008

          2. Hematology values must be within the following limits:

             A.Absolute neutrophil count 1000/mm3 independent of growth factor support B.Platelets
             100,000/mm3 or 50,000/mm3 if bone marrow involvement independent of transfusion
             support in either situation C.Hemoglobin ≥ 10.0 g/dL (may be transfused or
             erythropoietin treated)

          3. Biochemical values within the following limits:

             A.Alanine aminotransferase and aspartate aminotransferase≤ 3 x upper limit of normal
             B.Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of
             non-hepatic origin C.Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration
             Rate (Cockroft Gault) ≥ 40 mL/min/1.73m2 D.Serum calcium ≤ 12.0 mg/dL

          4. Women of childbearing potential and men who are sexually active must be practicing a
             highly effective method of birth control during and after the study consistent with
             local regulations regarding the use of birth control methods for subjects
             participating in clinical trials. Men must agree to not donate sperm during and after
             the study. For females, these restrictions apply for 1 month after the last dose of
             study drug. For males, these restrictions apply for 3 months after the last dose of
             study drug

          5. Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin)or urine pregnancy test at Screening. Women who are pregnant or
             breastfeeding are ineligible for this study.

          6. Sign (or their legally-acceptable representatives must sign) an informed consent
             document indicating that they understand the purpose of and procedures required for
             the study, including biomarkers, and are willing to participate in the study.

          7. At least one measurable lesion

          8. ECOG PS 0-2

          9. Informed consent

         10. Age ≥ 19 years

        Exclusion Criteria:

          1. Previous treatment history for EBV-positive DLBCL including any kinds of chemotherapy

             •Exception: a) Prednisolone 100mg or equivalent dosage of any types of steroid is
             allowed (Maximum 7 days); b) Radiation for reducing symptom related with mass effect
             is allowed

          2. History of or known carcinomatous meningitis, or evidence of symptomatic
             leptomeningeal disease or secondary CNS involvement on CT or MRI scan.

          3. Pregnancy or breastfeeding

          4. Major surgery within 4 weeks of enrollment

          5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment

          6. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,
             phenprocoumon).

          7. Requires treatment with strong CYP3A inhibitors.

          8. Clinically significant cardiovascular disease such as uncontrolled or symptomatic
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
             the New York Heart Association Functional Classification.

          9. Vaccinated with live, attenuated vaccines within 4 weeks of enrollment.

         10. Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or
             active Hepatitis B Virus infection or any uncontrolled active systemic infection
             requiring intravenous (IV) antibiotics.

         11. Any life-threatening illness, medical condition, or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
             risk.